Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLucas MixWVWichard VogelBBBritta Besemer

Discussion

Loading...

Member takes

Overview

Phase II trial evaluates Venetoclax-augmented Treosulfan safety and overall survival in AML and MDS, indicating promising outcomes after transplant.

Key Points

  • To assess the safety and feasibility of Venetoclax with Treosulfan in reducing relapse risk after transplantation.
  • Conducted as a monocentric, single-arm phase II trial.
  • Involves 27 patients with AML, MDS, or higher risk MDS planned for alloHSCT.
  • Administers Venetoclax for 7 days prior to transplant alongside Fludarabine and Treosulfan.
  • Hypothesized that adding Venetoclax reduces relapse risk without increasing toxicity.
  • Primary endpoint is overall survival at day 28 after alloHSCT.

Cite This Study

Mix et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba8https://doi.org/10.1182/blood-2025-6001
View Full Paper
Ask AI
Bookmark
Share